Confidentiality of Substance Use Disorder Patient Records, 1041-1042 [2018-00150]
Download as PDF
Federal Register / Vol. 83, No. 6 / Tuesday, January 9, 2018 / Notices
National Institute of Dental and Craniofacial
Research, National Institutes of Health,
Bethesda, MD 20892, 301–594–4805,
adombroski@nidcr.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: January 2, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–00155 Filed 1–8–18; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
meeting of the National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; MSM Program
Review (2018/05).
Date: February 12, 2018.
Time: 5:00 p.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy Plaza,
Suite 920, Bethesda, MD 20892 (Virtual
Meeting).
15:58 Jan 08, 2018
Dated: January 2, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–00154 Filed 1–8–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Confidentiality of Substance Use
Disorder Patient Records
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of public meeting.
AGENCY:
The Substance Abuse and
Mental Health Services Administration
(SAMHSA) announces that it will hold
a public listening session on
Wednesday, January 31, 2018, to solicit
information concerning the
Confidentiality of Substance Use
Disorder Patient Records regulations as
required by Section 11002 of the 21st
Century Cures Act. The listening session
will provide an opportunity for the
public to provide input to SAMHSA
concerning the effect of part 2 on
‘‘patient care, health outcomes, and
patient privacy’’ as well as potential
regulatory changes and future
subregulatory guidance.
DATES: The listening session will be
held on Wednesday, January 31, 2018,
from 8:30 a.m. (Eastern) to 1:00 p.m.
(Eastern).
FOR FURTHER INFORMATION CONTACT: For
information concerning the listening
session, please contact Rachel Karton,
Senior Legislative and Regulatory
Analyst, SAMHSA, 5600 Fishers Lane,
Rockville, MD 20857, (240) 276–0416 or
email PrivacyRegulations@
SAMHSA.hhs.gov.
SUPPLEMENTARY INFORMATION:
Participation: The Listening Session
proceeding will be recorded, and
subsequently archived and posted on
the SAMHSA website. The public may
attend the listening session:
• Via Teleconference/Webcast: The
entire proceeding will be streamed live
over the internet (requires prior
registration). Audio and streaming
information will be sent to those who
register prior to the meeting. Capacity
SUMMARY:
BILLING CODE 4140–01–P
VerDate Sep<11>2014
Contact Person: Manana Sukhareva, Ph.D.,
Scientific Review Officer, National Institutes
of Biomedical Imaging and Bioengineering,
National Institutes of Health, 6707
Democracy Boulevard, Suite 959, Bethesda,
MD 20892, (301) 451–3397, sukharem@
mail.nih.gov.
Jkt 244001
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
1041
for the Teleconference/Webcast
participation is limited so early
registration is recommended.
• In Person: The address for this
meeting is 5600 Fishers Lane, 5th
(Main) Floor Pavilion rooms, Rockville,
Maryland 20852. The building is a
federal facility; prior registration, a
security screening and a federallyapproved identification (e.g., driver’s
license) are required to attend in-person.
Capacity for in-person attendance is
limited so early registration is
recommended.
Registration: Registration is required
for participation in the listening session
in person or via Teleconference/
Webcast. Registration is now open.
Registration for the in-person session
will close on 01/22/2018 at 12:00 p.m.
Eastern Time (ET). Registration for the
Teleconference/Webcast will close on
01/31/2018 at 8:30 a.m. ET. Persons
registering should indicate if they wish
to make a public comment. SAMHSA
recommends that when commenters
suggest changes or revisions to current
regulations that they indicate
specifically, when feasible, how such
regulation text should be revised. Only
one representative of an organization
may be allowed to present oral
comments. Presentations will be limited
to three minutes per speaker. SAMHSA
will try to accommodate all speakers
who wish to present based on the time
allotted for this meeting. Persons
making oral presentations are
encouraged to also submit written
comments as discussed below.
To register, go to: https://42-cfr-part2listening-session.eventbrite.com.
Special Assistance: Individuals who
plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify Rachel
Karton (contact information provided
below) at least 10 days prior to the
meeting.
Public Comments: In addition to
attending the session in person or
joining via Teleconference/Webcast, the
Agency offers several ways to provide
comments. SAMHSA recommends that
when commenters suggest changes or
revisions to current regulations that they
indicate specifically, when feasible,
how such regulation text should be
revised. You may provide comments
through the following means:
• Electronically: PrivacyRegulations@
SAMHSA.hhs.gov (preferred).
• Regular, Express or Overnight Mail,
or Hand Delivery or Courier: Written
comments must be sent to the following
address ONLY: Substance Abuse and
Mental Health Services Administration
(SAMHSA), Department of Health and
E:\FR\FM\09JAN1.SGM
09JAN1
sradovich on DSK3GMQ082PROD with NOTICES
1042
Federal Register / Vol. 83, No. 6 / Tuesday, January 9, 2018 / Notices
Human Services, Attn: Mitchell Berger,
SAMHSA, 5600 Fishers Lane, Room
18E89C, Rockville, Maryland 20852.
Due to the anticipated high volume of
comments, please note that receipt of
comments will not be acknowledged.
Comments must be received by 5:00
p.m. ET on Wednesday February 28,
2018.
Background: Title 42, section 290dd–
2, of the United States Code, pertaining
to Confidentiality of Records, provides
that ‘‘[r]ecords of the identity, diagnosis,
prognosis, or treatment of any patient
which are maintained in connection
with the performance of any program or
activity relating to substance abuse
education, prevention, training,
treatment, rehabilitation, or research,
which is conducted, regulated, or
directly or indirectly assisted by any
department or agency of the United
States shall [. . .] be confidential and be
disclosed only for the purposes and
under the circumstances expressly
authorized’’ by the statute or as
otherwise provided. The statute further
provides that such records may not be
‘‘used to initiate or substantiate any
criminal charges against a patient or to
conduct any investigation of a patient’’
without an appropriate court order.
The implementing regulations, 42
CFR part 2, were first promulgated as a
final rule on July 1, 1975 (40 FR 27802),
and substantively updated in 1987 (52
FR 21796). On February 9, 2016,
SAMHSA issued a notice of proposed
rulemaking (NPRM) regarding
substantive changes to part 2 (81 FR
6987) and on January 18, 2017,
SAMHSA finalized changes to these
regulations (82 FR 6052). The January
2017 final rule became effective on
March 21, 2017 (see 82 FR 10863, Feb.
16, 2017). This final rule was intended
to ‘‘ensure that patients with substance
use disorders have the ability to
participate in and benefit from health
system delivery improvements,
including from new integrated health
care models while providing
appropriate privacy safeguards.’’ The
final rule made substantive changes to
regulatory provisions regarding
Definitions (§ 2.11), Applicability
(§ 2.12), Confidentiality restrictions and
safeguards (§ 2.13), Security for records
(§ 2.16), Disposition of records by
discontinued programs (§ 2.19), Consent
requirements (§ 2.31), Re-disclosure
(§ 2.32), Medical emergencies (§ 2.51),
Research (§ 2.52), and Audit and
evaluation (§ 2.53).
Concurrently with finalizing these
changes, SAMHSA issued a
supplemental notice of proposed
rulemaking (SNPRM) on January 18,
2017, proposing additional changes to
VerDate Sep<11>2014
15:58 Jan 08, 2018
Jkt 244001
facilitate disclosures by lawful holders
to their contractors, subcontractors, and
legal representative for the purposes of
payment and health care operations and
for carrying out an audit or evaluation
and to permit disclosures by lawful
holders to those conducting audits and
evaluations on behalf of a governmental
agency providing financial assistance to
or regulatory oversight over the lawful
holder. SAMHSA also sought comments
on other topics, including an option for
an abbreviated prohibition on redisclosure notice. In January 2018,
SAMHSA published a final rule
implementing these changes.
In response to the 2016 NPRM and
since publication of the January 2017
final rule and the SNPRM, SAMHSA
has already heard from numerous
stakeholders on a range of issues
pertaining to part 2. For instance, some
commenters asserted that part 2 has
become a barrier to integration of care
and research. Many commenters also
have suggested that part 2 does not
adequately align with the Health
Insurance Portability and
Accountability Act (HIPAA). SAMHSA
also has received many comments
emphasizing the continuing importance
of part 2 in protecting patients who seek
substance use disorder treatment from
discrimination in housing, employment,
education, and other settings as well as
from criminal investigation and
penalties. Some commenters also have
urged SAMHSA to update part 2 penalty
provisions and prevent what they
believe to be misuse of patient
identifying information.
On December 13, 2016, the 21st
Century Cures Act was signed into law
(Pub. L. 114–255). Section 11002 of this
law requires that, within one year of the
effective date of the final rule, ‘‘the
Secretary [HHS] shall convene relevant
stakeholders to determine the effect of
such regulations on patient care, health
outcomes, and patient privacy.’’ The
listening session on January 31, 2018,
will solicit input focused on how part
2 impacts patient care, health outcomes
and patient privacy as well as potential
regulatory changes and future
subregulatory guidance. It is important
to note that any recommendations of
further changes to part 2 received
during this meeting could, even if
legally permissible and feasible, only be
implemented after notice-and-comment
as required by the Administrative
Procedures Act.
*
*
*
*
*
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Dated: January 3, 2017.
Charles LoDico,
Chemist.
[FR Doc. 2018–00150 Filed 1–8–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Center for Mental Health Services:
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration (SAMHSA),
Center for Mental Health Services
(CMHS) National Advisory Council
(NAC) will meet on February 14, 2018,
from 8:30 a.m. to 5:00 p.m. E.D.T. The
CMHS NAC will convene in both open
and closed sessions on February 14,
2018.
The closed portion of the meeting will
include discussion and evaluation of
grant applications reviewed by
SAMHSA’s Initial Review Groups, and
involve an examination of confidential
financial and business information as
well as personal information concerning
the applicants. Therefore, the meeting
will be closed to the public from 8:30
a.m. to 10:00 a.m. as determined by the
Assistant Secretary for Mental Health
and Substance Use, SAMHSA in
accordance with Title 5 U.S.C.
552b(c)(4) and (6) and Title 5 U.S.C.
App. 2, 10(d).
The remainder of this meeting will be
open to the public from 10:00 a.m. to
5:00 p.m., E.D.T., to include discussion
of the Center’s policy issues,
presentations on SAMHSA’s Policy Lab,
Disaster Responses and a conversation
with the Assistant Secretary for Mental
Health and Substance Use.
Attendance by the public will be
limited to available space. Interested
persons may present data, information,
or views, orally or in writing, on issues
pending before the council. Written
submissions should be forwarded to the
contact person (below) on or before
January 31, 2018. Oral presentations
from the public will be scheduled at the
conclusion of the meeting on
Wednesday, February 14, 2018. Five
minutes will be allotted for each
presentation. Meeting information and a
roster of Council members may be
obtained either by accessing the
SAMHSA Council website at https://
www.samhsa.gov/about-us/advisorycouncils/cmhs-national-advisory-
E:\FR\FM\09JAN1.SGM
09JAN1
Agencies
[Federal Register Volume 83, Number 6 (Tuesday, January 9, 2018)]
[Notices]
[Pages 1041-1042]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00150]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Confidentiality of Substance Use Disorder Patient Records
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: The Substance Abuse and Mental Health Services Administration
(SAMHSA) announces that it will hold a public listening session on
Wednesday, January 31, 2018, to solicit information concerning the
Confidentiality of Substance Use Disorder Patient Records regulations
as required by Section 11002 of the 21st Century Cures Act. The
listening session will provide an opportunity for the public to provide
input to SAMHSA concerning the effect of part 2 on ``patient care,
health outcomes, and patient privacy'' as well as potential regulatory
changes and future subregulatory guidance.
DATES: The listening session will be held on Wednesday, January 31,
2018, from 8:30 a.m. (Eastern) to 1:00 p.m. (Eastern).
FOR FURTHER INFORMATION CONTACT: For information concerning the
listening session, please contact Rachel Karton, Senior Legislative and
Regulatory Analyst, SAMHSA, 5600 Fishers Lane, Rockville, MD 20857,
(240) 276-0416 or email [email protected].
SUPPLEMENTARY INFORMATION:
Participation: The Listening Session proceeding will be recorded,
and subsequently archived and posted on the SAMHSA website. The public
may attend the listening session:
Via Teleconference/Webcast: The entire proceeding will be
streamed live over the internet (requires prior registration). Audio
and streaming information will be sent to those who register prior to
the meeting. Capacity for the Teleconference/Webcast participation is
limited so early registration is recommended.
In Person: The address for this meeting is 5600 Fishers
Lane, 5th (Main) Floor Pavilion rooms, Rockville, Maryland 20852. The
building is a federal facility; prior registration, a security
screening and a federally-approved identification (e.g., driver's
license) are required to attend in-person. Capacity for in-person
attendance is limited so early registration is recommended.
Registration: Registration is required for participation in the
listening session in person or via Teleconference/Webcast. Registration
is now open. Registration for the in-person session will close on 01/
22/2018 at 12:00 p.m. Eastern Time (ET). Registration for the
Teleconference/Webcast will close on 01/31/2018 at 8:30 a.m. ET.
Persons registering should indicate if they wish to make a public
comment. SAMHSA recommends that when commenters suggest changes or
revisions to current regulations that they indicate specifically, when
feasible, how such regulation text should be revised. Only one
representative of an organization may be allowed to present oral
comments. Presentations will be limited to three minutes per speaker.
SAMHSA will try to accommodate all speakers who wish to present based
on the time allotted for this meeting. Persons making oral
presentations are encouraged to also submit written comments as
discussed below.
To register, go to: https://42-cfr-part2-listening-session.eventbrite.com.
Special Assistance: Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify Rachel Karton (contact information
provided below) at least 10 days prior to the meeting.
Public Comments: In addition to attending the session in person or
joining via Teleconference/Webcast, the Agency offers several ways to
provide comments. SAMHSA recommends that when commenters suggest
changes or revisions to current regulations that they indicate
specifically, when feasible, how such regulation text should be
revised. You may provide comments through the following means:
Electronically: [email protected]
(preferred).
Regular, Express or Overnight Mail, or Hand Delivery or
Courier: Written comments must be sent to the following address ONLY:
Substance Abuse and Mental Health Services Administration (SAMHSA),
Department of Health and
[[Page 1042]]
Human Services, Attn: Mitchell Berger, SAMHSA, 5600 Fishers Lane, Room
18E89C, Rockville, Maryland 20852. Due to the anticipated high volume
of comments, please note that receipt of comments will not be
acknowledged. Comments must be received by 5:00 p.m. ET on Wednesday
February 28, 2018.
Background: Title 42, section 290dd-2, of the United States Code,
pertaining to Confidentiality of Records, provides that ``[r]ecords of
the identity, diagnosis, prognosis, or treatment of any patient which
are maintained in connection with the performance of any program or
activity relating to substance abuse education, prevention, training,
treatment, rehabilitation, or research, which is conducted, regulated,
or directly or indirectly assisted by any department or agency of the
United States shall [. . .] be confidential and be disclosed only for
the purposes and under the circumstances expressly authorized'' by the
statute or as otherwise provided. The statute further provides that
such records may not be ``used to initiate or substantiate any criminal
charges against a patient or to conduct any investigation of a
patient'' without an appropriate court order.
The implementing regulations, 42 CFR part 2, were first promulgated
as a final rule on July 1, 1975 (40 FR 27802), and substantively
updated in 1987 (52 FR 21796). On February 9, 2016, SAMHSA issued a
notice of proposed rulemaking (NPRM) regarding substantive changes to
part 2 (81 FR 6987) and on January 18, 2017, SAMHSA finalized changes
to these regulations (82 FR 6052). The January 2017 final rule became
effective on March 21, 2017 (see 82 FR 10863, Feb. 16, 2017). This
final rule was intended to ``ensure that patients with substance use
disorders have the ability to participate in and benefit from health
system delivery improvements, including from new integrated health care
models while providing appropriate privacy safeguards.'' The final rule
made substantive changes to regulatory provisions regarding Definitions
(Sec. 2.11), Applicability (Sec. 2.12), Confidentiality restrictions
and safeguards (Sec. 2.13), Security for records (Sec. 2.16),
Disposition of records by discontinued programs (Sec. 2.19), Consent
requirements (Sec. 2.31), Re-disclosure (Sec. 2.32), Medical
emergencies (Sec. 2.51), Research (Sec. 2.52), and Audit and
evaluation (Sec. 2.53).
Concurrently with finalizing these changes, SAMHSA issued a
supplemental notice of proposed rulemaking (SNPRM) on January 18, 2017,
proposing additional changes to facilitate disclosures by lawful
holders to their contractors, subcontractors, and legal representative
for the purposes of payment and health care operations and for carrying
out an audit or evaluation and to permit disclosures by lawful holders
to those conducting audits and evaluations on behalf of a governmental
agency providing financial assistance to or regulatory oversight over
the lawful holder. SAMHSA also sought comments on other topics,
including an option for an abbreviated prohibition on re-disclosure
notice. In January 2018, SAMHSA published a final rule implementing
these changes.
In response to the 2016 NPRM and since publication of the January
2017 final rule and the SNPRM, SAMHSA has already heard from numerous
stakeholders on a range of issues pertaining to part 2. For instance,
some commenters asserted that part 2 has become a barrier to
integration of care and research. Many commenters also have suggested
that part 2 does not adequately align with the Health Insurance
Portability and Accountability Act (HIPAA). SAMHSA also has received
many comments emphasizing the continuing importance of part 2 in
protecting patients who seek substance use disorder treatment from
discrimination in housing, employment, education, and other settings as
well as from criminal investigation and penalties. Some commenters also
have urged SAMHSA to update part 2 penalty provisions and prevent what
they believe to be misuse of patient identifying information.
On December 13, 2016, the 21st Century Cures Act was signed into
law (Pub. L. 114-255). Section 11002 of this law requires that, within
one year of the effective date of the final rule, ``the Secretary [HHS]
shall convene relevant stakeholders to determine the effect of such
regulations on patient care, health outcomes, and patient privacy.''
The listening session on January 31, 2018, will solicit input focused
on how part 2 impacts patient care, health outcomes and patient privacy
as well as potential regulatory changes and future subregulatory
guidance. It is important to note that any recommendations of further
changes to part 2 received during this meeting could, even if legally
permissible and feasible, only be implemented after notice-and-comment
as required by the Administrative Procedures Act.
* * * * *
Dated: January 3, 2017.
Charles LoDico,
Chemist.
[FR Doc. 2018-00150 Filed 1-8-18; 8:45 am]
BILLING CODE P